CAPTRUST Financial Advisors’s Provectus Biopharmaceuticals PVCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-57,659
Closed -$3K – 4662
2022
Q2
$3K Buy
57,659
+37,257
+183% +$1.94K ﹤0.01% 4388
2022
Q1
$1K Sell
20,402
-22,257
-52% -$1.09K ﹤0.01% 4834
2021
Q4
$2K Buy
42,659
+20,202
+90% +$947 ﹤0.01% 4494
2021
Q3
$1K Hold
22,457
– – ﹤0.01% 4557
2021
Q2
$2K Hold
22,457
– – ﹤0.01% 4256
2021
Q1
$2K Hold
22,457
– – ﹤0.01% 4119
2020
Q4
$1K Buy
+22,457
New +$1K ﹤0.01% 3361
2020
Q3
– Sell
-21,657
Closed -$1K – 3396
2020
Q2
$1K Buy
+21,657
New +$1K ﹤0.01% 2793

Other funds holding PVCT

CAPTRUST Financial Advisors's PVCT Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Provectus Biopharmaceuticals (PVCT) in Q3 2022, closing a stake of 57,659 shares — an estimated $3K sold.

CAPTRUST Financial Advisors first reported a position in PVCT in Q2 2020 and held it in 8 quarters. The position peaked at $3K in Q2 2022. 7 funds tracked by Wall St. Rank hold PVCT as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Provectus Biopharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 57,659 Provectus Biopharmaceuticals shares in Q3 2022, an estimated $3K.
  • CAPTRUST Financial Advisors first reported a position in Provectus Biopharmaceuticals in Q2 2020 and held it in 8 quarters.
  • CAPTRUST Financial Advisors's Provectus Biopharmaceuticals position peaked at $3K in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Provectus Biopharmaceuticals as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.